GlassScriptPhysician profile
Callie Grace Cichra
NPI 1619434818
$1,471.55
in general payments reported to CMS, 2019-2025
16 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $651 · 2023: $195 · 2024: $155 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $315.55 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $224.18 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $166.96 | 2021-2023 | Xarelto |
| Abiomed | $141.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.24 | 2022-2023 | Camzyos |
| Amgen INC. | $112.80 | 2021-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $94.90 | 2022-2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $71.67 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $46.72 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $45.00 | 2024 | Varithena Administration Pack |
| Esperion Therapeutics, INC. | $40.57 | 2023-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $25.12 | 2022 | |
| Novo Nordisk INC | $25.00 | 2025 | Wegovy |
| Genzyme Corporation | $16.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.02 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $8.68 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Cichra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.